Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease

@inproceedings{Bymaster1997XanomelineAS,
  title={Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease},
  author={Frank P. Bymaster and Celia A. Whitesitt and Harlan Edgar Shannon and Neil DeLapp and John S. Ward and David O. Calligaro and Lisa Ann Shipley and Judith L. Buelke-Sam and Neil Clayton Bodick and Lars Farde and Malcolm J. Sheardown and Preben H. Olesen and Kristian Tage Hansen and Peter D. Suzdak and Michael D B Swedberg and Per Sauerberg and Charles Mitch},
  year={1997}
}
Xanomeline is a novel muscarinic receptor agonist relatively devoid of parasympathomimetic side effects. Xanomeline had high affinity for muscarinic receptors and much lower affinity for a variety of other neuronal receptors in radioligand binding assays. Functional studies in cell lines transfected with the muscarinic receptor subtypes demonstrated that xanomeline had higher potency and efficacy for m1 and m4 receptors than m2, m3, and m5 receptor subtypes. Similarly, in isolated tissue… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 28 CITATIONS

Problems and solutions to filling the drying drug pipeline for psychiatric disorders: a report from the inaugural 2012 CINP Think Tank.

  • The international journal of neuropsychopharmacology
  • 2014
VIEW 6 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Persistent binding and functional antagonism by xanomeline at the muscarinic M5 receptor.

  • The Journal of pharmacology and experimental therapeutics
  • 2005
VIEW 7 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Muscarinic M1 receptor agonists: can they improve cognitive performance?

  • The international journal of neuropsychopharmacology
  • 2013
VIEW 1 EXCERPT
CITES BACKGROUND